• Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Charles Patrick Davis, MD, PhD
    Charles Patrick Davis, MD, PhD

    Charles Patrick Davis, MD, PhD

    Dr. Charles "Pat" Davis, MD, PhD, is a board certified Emergency Medicine doctor who currently practices as a consultant and staff member for hospitals. He has a PhD in Microbiology (UT at Austin), and the MD (Univ. Texas Medical Branch, Galveston). He is a Clinical Professor (retired) in the Division of Emergency Medicine, UT Health Science Center at San Antonio, and has been the Chief of Emergency Medicine at UT Medical Branch and at UTHSCSA with over 250 publications.


BRAND NAME: Kinlytic (This drug is discontinued in the US)

DRUG CLASS AND MECHANISM: Urokinase is a thrombolytic medication made from human neonatal kidney cells. Urokinase is an enzyme (protein) that disrupts the clotting cycle and breaks down blood clots lodged in the lungs in people with pulmonary embolism. The FDA approved urokinase under the brand name Kinlytic in 2007.



PREPARATIONS: Urokinase available as sterile, lyophilized powder for solution for intravenous administration. Each vial contains 250,000 international units of urokinase activity.

STORAGE: Store urokinase vials in the fridge between 2 C to 8 C (36 F to 46 F).

PRESCRIBED FOR: Urokinase is prescribed for breakdown of pulmonary emboli, which are clots lodged in the lungs.

DOSING: Administer a loading dose of 4400 international units per kg intravenously over 10 minutes, followed by a continuous administration of 4400 international units per kg per hour intravenously for 12 hours. Repeat as necessary.

Safe and effective use of urokinase is not established for children.

DRUG INTERACTIONS: Urokinase should be used with caution with other medications that alter platelet function and increase risk of bleeding. Medications like aspirin, ibuprofen (Motrin), naproxen (Aleve, Naprosyn), warfarin (Coumadin), enoxaparin (Lovenox), clopidogrel (Plavix), and cilostazol (Pletal) should be used with caution with urokinase.

FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Newsletters

Get the latest health and medical information delivered direct to your inbox!

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors